Status:
COMPLETED
Analysis of Expression of Specific Markers and Their Prognostic Significance in Hepatocellular Carcinoma
Lead Sponsor:
GlaxoSmithKline
Conditions:
Hepatocellular Carcinoma
Eligibility:
All Genders
Brief Summary
Hepatocellular carcinoma is an aggressive disease with limited therapeutic options. Therefore, new approaches to treat this type of cancer are needed with immunotherapy potentially being one of these....
Eligibility Criteria
Inclusion
- The patient has pathologically proven hepatocellular carcinoma (any stage)
- All the data required are available from patient's records
Exclusion
- N/A
Key Trial Info
Start Date :
November 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2009
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT00911196
Start Date
November 1 2008
End Date
March 1 2009
Last Update
May 30 2017
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Taipei, Taiwan, 100
2
GSK Investigational Site
Bangkok, Thailand, 10700
3
GSK Investigational Site
Chiang Mai, Thailand, 50200